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1  | INTRODUC TION
The world will remember 2020 as the year of the coronavirus dis-
ease 2019 (COVID- 19) pandemic. In fact, in the winter of 2019, a 
new virus reportedly originating from the Hubei province in China, 
spread rapidly first to Italy, then France and Spain, causing millions 
of infections and tens of thousands of deaths. This virus, severe 
acute respiratory syndrome coronavirus- 2(SARS- CoV- 2), belong-
ing to the Coronaviridae family, is responsible for an acute respi-
ratory distress syndrome. In addition to the typical respiratory 
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Abstract
Background & Aims: Severe acute respiratory syndrome coronavirus- 2 (SARS- CoV- 2) 
is responsible for coronavirus disease 2019 (COVID- 19), which in males, especially in 
advanced age, can sometimes evolve into acute respiratory distress syndrome. In ad-
dition, mild to moderate alterations in liver function tests (LFTs) have been reported 
in the worst affected patients. Our review aims to analyse data on the incidence and 
prognostic value of LFT alterations, the underlying mechanisms and the management 
of pre- existing liver disease in COVID- 19 affected patients.
Methods: We searched available literature through online PubMed database using 
terms as “SARS- CoV- 2,” “Liver damage,” “Liver Function tests,” “COVID- 19,” “pre- 
existing liver disease,” “drug- induced liver injury.”
Results: Available evidence suggest that there could be a relationship between SARS- 
CoV- 2 infection and liver damage, although the underlying involved mechanism re-
mains unclear. Cohort studies have shown that high ALT levels, low platelet counts 
and low albumin levels at admission and during hospitalisation are associated with 
a high mortality rate. Unfortunately, little is known about the impact of COVID- 19 
on pre- existing liver damage. While chronic viral infections or NAFLD are associated 
with an increased risk of COVID- 19 progression, patients with cirrhosis may have in-
creased susceptibility to SARS- CoV- 2 infection due to their systemic immunocompro-
mised status. DILI seems common among hospitalised patient with severe pneumonia.
Conclusion: Mild to moderate liver impairment during Covid- 19 is common, espe-
cially in patients with pre- existing liver disease. Further studies should be performed 
in order to understand how pre- existing liver conditions may influence and worsen 
progression of liver disease in COVID- 19 patients.
This is an open access article under the terms of the Creative Commons Attribution- NonCommercial- NoDerivs License, which permits use and distribution in 
any medium, provided the original work is properly cited, the use is non- commercial and no modifications or adaptations are made.
© 2021 The Authors. GastroHep published by John Wiley & Sons Ltd.
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signs and symptoms, mild to moderate alterations in liver function 
tests (LFTs) have been reported in the worst affected patients. 
LFT alterations, and in particular aminotransferase (AST and ALT) 
values, are a frequent manifestation of SARS- CoV- 2 infection and 
are associated with an increase in lactic dehydrogenase (LDH) 
and inflammation markers such as C- reactive protein and ferri-
tin. Many reports, all from studies conducted in China, show that 
abnormal liver tests and liver injury, mostly hepatocellular rather 
than cholestatic, are frequent in patients with COVID- 19,1- 10 as 
reported in Table 1. Data from Chinese studies have shown that 
about 2%- 11% of patients hospitalised for COVID- 19 have one or 
more liver comorbidities and 14%- 53% of patients show altered 
LFT values.2 Cai et al defined liver injury as an alteration in trans-
aminases (AST or ALT) up to 3 X ULN and/or alkaline phosphatase 
(ALP), gamma- glutamyl transferase (GGT), total bilirubin up to 2 X 
ULN, and reported this condition in 5% of patients at admission 
and in 21.3% during hospitalisation, whereas 76% did not show any 
dysfunction.3 These figures emphasise the differences between 
liver injury and the slight alterations in LFTs, which usually occur in 
systemic viral infections and may reflect systemic immune activa-
tion or inflammation induced by circulating cytokines, without an 
impairment of liver function.
Severe COVID- 19 disease, however, appears to be more fre-
quently associated with liver injury. Huang observed an eleva-
tion in AST of up to 5 X UNL in 8 of the 13 patients admitted 
to the ICU (62%) and in 7 of the 28 outpatient patients (25%).2 
In a large cohort of 1099 patients, abnormal aminotransferase 
levels were more frequently found in severe COVID- 19 patients 
than in non- severe patients (18% in mild COVID- 19 disease vs 
28% in severe disease).1 Rarely, SARS- CoV- 2 infection can pres-
ent as acute hepatitis, with transaminases 10- 20 X ULN at admis-
sion, with all other causes of acute hepatitis having been ruled 
out.11
Some studies have reported LFT values obtained at admission, 
during hospitalisation and at discharge to evaluate the detrimen-
tal effect on the liver of certain drugs used during hospitalisa-
tion. Fan et al showed that 37.2% of patients had abnormal liver 
function at admission, whereas a significantly higher proportion 
of patients showed abnormal liver function (57.8%) after receiving 
lopinavir/ritonavir than other patients not receiving these drugs 
(31.3%).7
However, although a number of studies have observed a slight 
increase in aminotransferases in hospitalised patients, and others 
have reported the worsening of a pre- existing liver condition due 
to the superimposed viral infection and to the hepatotoxicity of the 
treatment drugs, the relationship between pre- existing liver disease 
and COVID- 19 disease has not yet been carefully studied. A per-
centage of increased risk of SARS- CoV- 2 infection ranging from 2% 
to 11%, has been reported in NAFLD, alcohol liver disease or HBV 
hepatitis,1- 3,5,11 but it remains to be determined whether patients 
with cirrhosis and COVID- 19 have an increased risk of mortality due 
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2  | PATHOPHYSIOLOGY OF VIRUS 
INFEC TION
It has been clearly shown that the SARS- CoV- 2 virus enters cells by 
binding the angiotensin conversion enzyme- 2 (ACE2) receptor simi-
larly to SARS- CoV.12
Although many studies show that COVID- 19 is associated with 
liver injury, the underlying mechanism is not yet known. However, 
several hypotheses have been formulated: direct cytopathic effects, 
immune imbalance and cytokine storm with secondary multi- organ 
dysfunction, ischaemia and/or hypoxia- reperfusion injury and, fi-
nally, drug- induced liver injury (Figure 1).
2.1 | Direct cytopathic effect
Liver injury in COVID- 19 patients might be directly caused by the 
viral infection of liver cells. A recent study sequencing RNA on 
liver tissue samples from four donors who had died from cardio- 
circulatory arrest revealed that both hepatocytes and bile duct cells 
express ACE2 receptors with a high affinity for the spike protein of 
SARS- CoV- 2. However, the expression levels of these receptors in 
cholangiocytes are about 20 times higher than in hepatocytes and 
comparable to expression in alveolar type II cells.13 Furthermore, the 
epithelium of bile ducts plays an important role in liver regenera-
tion and in the regulation of immune response.14 In cholangiocytes 
the virus replicates actively and decreases claudin- 1 expression, de-
termining tight junction disruption between cholangiocytes and in 
turn the impairment of bile acid transport and function. Some stud-
ies have seen that ductal cells are usually susceptible to infections, 
with a consequent impairment of barrier function and the transport 
of bile acids.15 Hepatocytes, on the other hand, are not particularly 
affected by SARS CoV- 2, as there is a reduction in or lack of ACE2 
receptors. From this, it can be deduced that liver damage is perhaps 
not directly linked to the activity of the virus, but there is probably 
another etiological trigger.
Among the aetiological hypotheses, many authors have argued 
that liver damage is likely due to the action of immune cells activated 
in response to the virus and the resulting cytokine activity.13 In a 
respiratory viral infection, collateral liver injury has been related to 
virus- specific effector cells generated in response to pulmonary in-
fection. Analysis of post- mortem liver biopsies of patients infected 
with SARS- CoV- 2 showed hepatocyte degeneration, focal necrosis, 
inflammation of bile ducts and portal and peri- portal inflammation, 
as well as fat degeneration,4 but no viral particles were found. The 
absence of viral particles in the liver, therefore, indicates that liver 
damage is probably primarily related to the action of activated T 
cells, in particular Th- 17 and CD811 ; a case of microvesicular ste-
atosis was observed with hyperactivation of T cells, reinforcing the 
hypothesis of immune- mediated damage rather than a cytopathic 
effect, as has recently been argued.5
2.2 | Immune imbalance and cytokine storm
Immune dysfunction (including lympho- penia, a decrease in CD4+ 
T- cell levels, and abnormal cytokine levels with cytokine storm) in 
COVID- 19 patients is associated with disease severity and mortal-
ity.6 High levels of pro- inflammatory cytokines (TNF- a, IL- 6, IL- 2, IL- 
7, IL- 11, interferon γ, monocyte chemoattractant protein- 1/MCP- 1, 
and macrophage inflammatory protein 1- α) are responsible for the 
cytokine storm, which correlates to increased vascular permeability, 
F I G U R E  1   Pathogenetic mechanism of SARS- CoV 2 infection and multi- organ involvement cytokine storm
Direct virus effect ACE-2 receptor hepatocytes, 
cholangiocytes
Systemic cytokinestorm PCR, IL-6, Neutrophils,  
Lymphocytes
Hypoxemia and shock           Complication of cytokines storm
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multi- organ failure (MOF), the activation of coagulation pathways 
and in severe cases, even death.16 The state of systemic inflamma-
tion also causes an imbalance in coagulative homeostasis toward 
a pro- coagulant state, which predisposes to the onset of micro- 
thrombosis, disseminated intravascular coagulation and MOF.17
2.3 | Reperfusion- hypoxia syndrome
Hypoxia and shock induced by acute respiratory distress syndrome, 
systemic inflammatory response syndrome, and multiple organ fail-
ure may cause hepatic hypoperfusion and dysfunction secondary to 
hypoxia reperfusion. The reduction in oxygen levels (and the con-
sequent lipid accumulation) during shock and other hypoxic condi-
tions, could lead to hepatocyte necrosis. Overall, the damage that 
occurs, the increase in reactive oxygen species and the products 
generated during the reactions can activate some transcription fac-
tors and act as second messengers, further increasing the release of 
pro- inflammatory cytokines.4,8,18 It is well known that hypoxia is a 
relevant factor involved in liver damage from COVID- 19.
3  | DRUG - INDUCED LIVER INJURY IN 
COVID - 19
Liver injury during SARS- CoV- 2 infection may also be related to drug 
hepatotoxicity, especially 7- 10 days after disease onset, which ex-
plains the great variability observed in the different cohort studies in 
the literature, due to the different drugs used to manage COVID- 19. 
Treatment of infection involves the use of multiple medications 
such as anti- pyretic, anti- microbial, anti- viral and anti- fungal drugs 
and steroids, which have all been seen to be potential causes of 
liver damage, although there is still no strong evidence to support 
this.19 Consequently, in patients with COVID- 19 there has been an 
increased incidence of liver dysfunction not only directly related to 
the action of the virus, but also to the side effects of the drugs used 
in its management 2 (see Table 2).
Among the drugs initially licensed for use against COVID- 19 was 
chloroquine; in vitro studies have shown its important activity in 
the inhibition of viral replication and also a certain effectiveness in 
vivo.20 Chloroquine acts either by stopping the cytokine storm or by 
blocking the activation of CD8+ cells.21 However, its use has been 
linked in the past to the onset of fulminating hepatitis.22 In combi-
nation with chloroquine, azithromycin, a broad- spectrum macrolide, 
has been used due to its presumable anti- inflammatory activity, but 
it is a common cause of hepatotoxicity (DILI) after about 1- 3 weeks 
of treatment.23 A retrospective cohort study of 134 patients showed 
that treatment with chloroquine/azithromycin led to a clinical im-
provement in 26.8% of patients and although ICU transfer rate and 
mechanical ventilation, as well as mortality at day 28 were higher in 
the treatment group compared to controls (p 0.03), no differences 
in LFTs were found between the two groups.24 In a randomised 
controlled multicenter trial,25 which included 667 patients treated 
with hydroxychloroquine alone or in combination with azithromy-
cin versus standard treatment, QT interval prolongation and LFTs 
alterations were shown to be more frequent in treated than in un-
treated patients. Therefore, among hospitalised patients, the use of 
hydroxychloroquine, alone or with azithromycin, does not improve 
the clinical condition after 15 days of treatment, compared to stan-
dard therapy, but could instead be responsible for the appearance of 
adverse events such as DILI or QT interval prolongation.
Most COVID- 19 patients with a very high fever have been 
treated with anti- pyretic agents containing paracetamol, one of 
the drugs mainly responsible for dose- dependent liver damage 
and acute liver failure. In particular, patients presenting with 
NAFLD are more susceptible to liver injury from acetaminophen 
at lower doses than the healthy population. For this reason, the 
US Food and Drug Administration suggested lowering the daily 
paracetamol dosage normally used in patients with pre- existing 
liver damage (from 4g to 3g) and the maximum single dosage from 
1g to 0.65 g.26 Unfortunately, this recommendation has not been 
accepted globally, and patients with COVID- 19 and metabolic 
syndrome, have been continuously exposed to the risk of severe 
hepatotoxicity.
Drugs Type of DILI Mechanism of liver injury
Chloroquine Hepatocellular Hypersensitivity, idiosyncratic




Acetaminophen Hepatocellular Dose- dependent
Lopinavir/ritonavir Hepatocellular, cholestatic or 
mixed
Due to liver metabolism by the 
cytochrome P450 system (CYP3A4), 
which may result in the production of 
a toxic intermediate
Tocilizumab Hepatocellular, predominantly 
cholestatic
Linked to effects on the immune 
system or on the IL- 6 pathway, which 
is important in liver regeneration
Remdesivir Hepatocellular Idiosyncratic
TA B L E  2   Type of DILI and mechanism 
of damage of different approved drugs 
used for therapy of COVID- 19, adapted 
from Liver Tox
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The liver is involved in the metabolism of most drugs, includ-
ing nucleoside analogues and protease inhibitors, also currently 
being tested in the management of COVID- 19. An increase in ami-
notransferases, if elevated up to 4- 5 X ULN, could be a sign of 
hepatotoxicity triggered by these drugs. A recent study reported 
that the use of lopinavir/ritonavir, as an antiviral treatment against 
SARS- CoV- 2 infection, was associated with an alteration of LFTs 
and an increase in bilirubin serum levels in patients with severe 
disease.27 In another series of cases, 55.4% of patients apparently 
reported severe liver damage after treatment with lopinavir/ri-
tonavir.28 Fan et al published a retrospective study in which they 
observed that the use of this drug combination was significantly 
higher in patients with abnormal LFT than in patients without 
LFT changes (56.1% vs. 25%, P < 0.009). In this study, 47.3% of 
discharged patients had elevated LFTs at baseline and 23.7% de-
veloped abnormalities during hospitalisation, suggesting that the 
emerging liver injury was likely due to medication rather than in-
fection.7 Moreover alterations in LFTs were associated with a long 
duration of hospitalisation. It is well documented that patients 
with viral infections (hepatitis C or HIV virus) are prone to devel-
oping drug- induced liver damage (DILI),29 particularly following 
the use of antiretroviral therapy, and more specifically HAART 
therapy.30 It is not known, whether SARS- CoV- 2 infection also 
predisposes to DILI.
Another therapeutic tool in the treatment of COVID- 19 is tocili-
zumab— a humanised anti- IL- 6 receptor monoclonal antibody used 
in patients with severe lung damage and high blood levels of IL- 6.31 
During clinical trials, a slight increase in LFTs was observed, but it 
was transient and resolved within 2- 6 weeks after commencement 
of treatment.32 Several trials are currently under way, aimed at re-
ducing ICU admissions. However, the safety of this therapy must 
be carefully monitored, as immunosuppression could lead to an in-
crease in the rate of bacterial infections, adversely affecting the clin-
ical condition of patients, especially those in ICU. The use of these 
immunosuppressive therapies in other diseases occasionally causes 
fulminant liver failure due to the reactivation of HBV infection in 
chronic carriers.32
Remdesivir is an antiviral inhibitor of RNA polymerase, recently 
approved in the treatment of patients with severe pneumonia from 
severe COVID- 19. Liver toxicity results have been contradictory, 
however, and it seems that remdesivir can lead to renal failure or 
liver dysfunction.33,34 Zampino et al described five cases of patients 
treated with remdesivir with raised AST/ALT levels, suggesting 
hepatocellular injury, but without liver failure.35 However, DILI in 
Covid- 19 hospitalised patients was of 25.4%, as recently reported 
in a meta- analysis.36
Convalescent plasma is frequently administered to critically ill 
patients with Covid- 19 and has been reported to improve clinical 
outcomes. Given the observational data, coming from case series, 
and those reported from randomised controlled trial, it seems that 
no significant differences were observed in clinical status or over-
all mortality between patients treated with convalescent plasma 
and those receiving placebo.37 Infusion- related adverse events 
were slightly more common in the convalescent plasma group 
(4.8%; 11 out of 228 patients) than in the placebo group (1.9%; 2 
out of 105 patients) (OR 2.62; 95% CI, 0.57- 12.04). Five patients in 
the convalescent plasma group and none in the placebo group had 
non- haemolytic febrile reactions. Increasing of LFTs of any grade 
have been reported in the convalescent plasma group as 9.6% (22 
out of 228) vs 7.6% (7 out of 109). Thus, no significant differences 
were found in the overall incidence of adverse events (OR 1.21; 
95% CI, 0.74 −1.95). However, multiple uncertainties exist regard-
ing to efficacy, appropriate donor selection and neutralizing anti-
bodies titres.38
Data regarding clinical trials with monoclonal antibodies, involv-
ing patients with Covid- 19, have been reported by two groups of 
researchers. In the first study, Weinreich et al, 39 reported results 
related to the study of a combination of two monoclonal antibod-
ies, casirivimab and imdevimab (REGN- COV2), directed against the 
SARS- CoV- 2 spike protein. The study enrolled outpatients, within 
7 days of symptom onset and within 72 hours of a positive naso-
pharyngeal swab. Both doses of REGN- COV2 were associated with 
few, mainly low- grade, side effects, and none showed increasing 
of LFTs. These results complement those obtained by Chen et al,40 
which evaluated three doses of a single monoclonal antibody, bam-
lanivimab, administered to outpatients presenting with Covid- 19 
within 4 days of the onset of symptoms. Reductions in viral RNA 
levels were detected after 3 days of treatment in all groups; only 14 
patients were hospitalised: 5 (1.6%) in the bamlanivimab group and 
9 (6.3%) in the placebo. No serious adverse events were registered; 
the percentage of patients who experienced an adverse event during 
treatment was 22.3% in the treatment group and 24.5% in placebo 
group. Diarrhoea, vomiting and nausea were adverse events com-
monly described in a percentage of cases lower than 5% in both the 
groups. Infusion- related reactions were mild and reported in 2.3% of 
the treatment group as compared with 1.4% in the placebo group. 
Alteration of LFTs was not reported.
These exciting results suggest that monoclonal antibodies acting 
as an antiviral agent useful for reducing viral load, seems to be fun-
damental for the treatment of early Covid- 19, as to avoid hospitalisa-
tions and overload for the health system. Many other trials are still 
ongoing in qualified nursing facilities and among family contacts of 
patients with SARS- CoV- 2 infection. However, till now, alteration of 
LFTs and liver injury in patients treated with both those monoclonal 
antibodies have never been reported.
4  | PRE-  E XISTING LIVER DISE A SE DURING 
COVID - 19
The relationship between pre- existing liver disease and COVID- 19 
has not been carefully studied. It is unclear if chronic liver disease 
should be considered a risk factor. However, it is important for 
clinicians to understand the importance of proper clinical monitor-
ing via LFTs during hospitalisation, especially in patients with pre- 
existing liver damage, as viral hepatitis and/or NAFLD. Particular 
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attention should also be paid to patients with liver cirrhosis and/or 
cancer, as their systemic immune impairment status makes these 
patients more susceptible to SARS- CoV- 2 infection and therefore 
requires greater clinical care, through strictly personalised thera-
peutic protocols.
4.1 | COVID- 19 and NAFLD
The acute Covid- 19 pandemic is superimposed on a much slower 
but equally widespread epidemic, namely metabolic diseases, as 
obesity and diabetes, resulting from the growing spread of an inad-
equate lifestyle characterised by excessive consumption of calories 
and scarce, if not absent, physical activity. This metabolic condi-
tion, predispose to a more severe Covid- 19 disease, with greater 
morbidity and mortality. Diabetes and obesity accentuate the clini-
cal response to SARS- COV- 2 infection, trigger an altered immune 
response, which is associated with an atherothrombotic state, and 
finally maintain an active chronic systemic inflammatory status 
responsible for severe complications, as septic shock, ARDS and 
multi- organ failure. The forced lockdown also contributed to reduc-
ing the possibility of physical activity, and at the same time, deter-
mining an increase in nutritional intake. Furthermore, the reduced 
exposure to the sunlight entails a decrease in vitamin D levels, and 
thus a reduction in anti- inflammatory activity and consequently an 
enhancement of insulin resistance, which is the main player of the 
metabolic syndrome.41 NAFLD represents the hepatic component of 
the metabolic syndrome. This condition affects almost one quarter 
of the Western population, mostly obese, and to date there is no ap-
proved drug therapy. Although hepatic steatosis is a benign disease, 
about 20%- 30% of patients develop necro- inflammation and hepatic 
fibrosis (non- alcoholic steatohepatitis- NASH) with the possibility of 
evolving towards cirrhosis. Due to the lack of effective therapies 
and the spread of obesity, post- NASH liver cirrhosis is currently 
the leading cause of liver transplantation. Recently, an international 
group of experts raised the question of the lack of consistency of the 
term NAFLD and proposed that of Metabolic Associated Fatty Liver 
Disease, as MAFLD.42
The increased incidence of NAFLD poses the risk of a large per-
centage of the population developing severe complications from 
COVID- 19.43 A high concentration of ACE2 receptors has been ob-
served in the small intestine epithelium, which explains the pres-
ence of symptoms such as abdominal pain and diarrhoea in infected 
subjects. The virus then reaches the liver by means of the portal 
circulation.44 The liver contains a high number of resident macro-
phages, Kupffer cells, which could play a crucial role in liver damage 
following the activation and release of pro- inflammatory cytokines. 
It should also be noted that NAFLD promotes the activity of M1 
macrophages, which produce pro- inflammatory cytokines, and sup-
presses the activity of M2 macrophages, thus contributing to the 
progression of damage from COVID- 19.45 Understanding the role 
of NAFLD in COVID- 19 disease could have important therapeutic 
and clinical implications. Therefore, patients with COVID- 19 with 
pre- existing liver diseases such as NAFLD, and even more so if they 
are male and in advanced age, should be closely monitored and 
strongly supported with heparin at a suitable therapeutic dose.
4.2 | COVID- 19 and alcoholic liver disease
Social distancing needed to fight the pandemic, and stress, isolation 
and depression caused by the lockdown resulted in a significant in-
crease in alcohol consumption and related diseases (ALD). Alcoholic 
liver disease is often associated with diabetes and chronic renal fail-
ure, both comorbidities that increase the risk of severe Covid- 19. In 
particular, in patients with alcoholic steatohepatitis, the use of cor-
ticosteroids could lead to an immunosuppressive effect that would 
further increase the risk of having a more severe Covid- 19.46
To date, no specific guidelines are available regarding the man-
agement of alcoholic hepatitis during COVID- 19, and existing studies 
recommend caution about steroids administration in patients in-
fected with SARS- CoV- 2.47 The pandemic has also raised walls about 
patients with ALD being considered for liver transplantation, result-
ing in both increased risk for relapse and difficulties in maintaining 
linkage to care. Initial observations that the use of non- steroidal 
anti- inflammatory drugs (NSAIDs) worsened the COVID- 19 disease, 
led to the increasing use of paracetamol, and even if this type of indi-
cation is no longer currently accepted, this has led to a rising in hep-
atotoxicity due to the combined use of paracetamol and alcohol. 48,49
4.3 | COVID- 19 and viral hepatitis (HBV/HCV)
In patients with chronic hepatitis B in immunotolerant phases with 
viral suppression under long- term treatment with nucleos(t)ide 
analogues, evidence of persistent liver injury and active viral rep-
lication after co- infection with SARS- CoV- 2 needs to be further 
investigated.50
Various studies have shown that chronic viral hepatitis does not 
appear to increase the risk of a severe course of COVID- 19 or extend 
the duration of hospitalisation.51,52
COVID- 19 patients co- infected with chronic HBV could risk hep-
atitis B reactivation. It is therefore necessary to monitor liver func-
tion as well as HBV- DNA levels,52 Zou et al studied four patients with 
chronic HBV- infection, who were finally diagnosed as ACLF due to a 
rapid deterioration in function after SARS- CoV- 2 co- infection with, 
progressively, jaundice, coagulation dysfunction and ascites. Liver 
injury in patients with SARS- CoV- 2 and chronic HBV co- infection 
has been associated with severity and poor prognosis of disease.53
A recently published retrospective study on the incidence of 
SARS- CoV- 2 infection in HCV- infected patients highlights how the 
rate of positivity is extremely low. SARS- COV- 2 infection appears to 
mainly affect obese and diabetic individuals; however, the degree of 
hepatic fibrosis does not appear to correlate with an increased risk 
of infection, either in patients with active HCV infection or in those 
already treated and who achieved eradication.54
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Despite the rearrangements made within hospitals during lockdown, 
and the consequent reduction in outpatient visits, the commencement 
of antiviral therapies for HCV and HBV should be promoted, especially 
in patients with more advanced liver disease and comorbidities.
4.4 | COVID- 19 and liver diseases requiring 
immunosuppression
In general, patients treated with immunosuppressants are considered 
to be at greater risk of serious complications from COVID- 19. However, 
no data suggest that in these patients there is an increased suscepti-
bility to infection. Patients with autoimmune hepatitis (AIH), primitive 
biliary cholangitis (PBC), overlap syndromes and primitive sclerosing 
cholangitis have a disrupted immune response that may be relevant in 
SARS- CoV- 2 infection. Since ACE2 receptors are expressed in chol-
angiocytes, infection with SARS- CoV- 2 could aggravate cholestasis in 
patients with primary biliary cholangitis. In patients with autoimmune 
hepatitis and COVID- 19, the effects of glucocorticoid administration 
on the liver disease are unclear. Immunosuppression may prolong the 
infectious state but reducing the dose or interrupting the immuno-
suppressant may cause a flare- up in a patient with AIH. In patients 
with a new onset of liver disease, diagnosis and treatment should not 
be delayed. The APASL and AASLD guidelines47 suggest maintaining 
the usual dose for patients on immune- suppressants without infec-
tion. By contrast, in COVID- 19 patients it is recommended to reduce 
the corticosteroid to a dose that avoids the onset of adrenal insuf-
ficiency, while reducing the dosages of azathioprine, mycophenolate 
mofetil or calcineurin inhibitor should be considered, especially in a 
context of lymphoma or worsening pneumonia.
4.5 | COVID- 19 and cirrhosis /liver cancer
Patients with cirrhosis or liver cancer could be more prone to develop-
ing a SARS- CoV- 2 infection and to a more severe course due to their 
systemic immunocompromised status. However, there are no data re-
garding severity, mortality and incidence of complications (infections, 
hepatic encephalopathy, bleeding from varices, liver failure).47 An Italian 
study showed that SARS- CoV- 2 infection was associated with liver 
function deterioration and elevated mortality in patients with cirrhosis, 
whether compensated or decompensated. The main causes of death 
were respiratory complications but also the sudden worsening of liver 
function.55 Further studies should focus on the effect of COVID- 19 on 
existing liver comorbidities and treatment outcomes. In cirrhotic pa-
tients, it is essential to continue follow- up to avoid worsening the un-
derlying chronic liver disease or underestimating a liver cancer.
4.6 | COVID- 19 on Liver Transplantation (LT)
Covid- 19 in LT recipients is unfortunately responsible for a greater 
number of cases who are hospitalised in intensive care unit (ICU) 
due to severe pneumonia requiring mechanical ventilation. These 
patients also have a higher risk of liver damage, evident from altera-
tion of the LFTs, which depends not only on the state of immune- 
suppression related to the transplant, but also on comorbidities, such 
as diabetes, cardiovascular and renal diseases, and the considerable 
risk of severe drug- drug interactions. One of the few recent studies 
that analysed this clinical setting highlighted how age, Hispanic race, 
metabolic syndrome, the use of antibiotics and vasopressor were 
able to predict the onset of liver damage, and also its multifacto-
rial nature.56 Furthermore, liver injury was independently associated 
with increased mortality. Thus, following LFTs in a LT recipient with 
Covid- 19, as a warning of liver damage, could help to identify pa-
tients at risk for a poor outcome.57
5  | MANAGEMENT OF LIVER PATIENTS 
WITH COVID - 19
In patients with a mild COVID- 19, liver injuries are often transient 
and self- limiting.58 Average levels of AST, ALT and serum bilirubin 
are significantly higher in severe or critical cases,59 such as a re-
duction in serum albumin.60 According to recent studies, there is 
no specific treatment for liver injury during COVID- 19, although in 
patients with severe liver damage it is advisable to administer medi-
cations with a hepatic- protective effect.50 The presence of altered 
liver enzymes should not be considered a contraindication to the 
use of experimental or off- label therapies for COVID- 19. However, 
high transaminase levels (five times the baseline value) exclude pa-
tients from experimental treatment. In particular, patients treated 
with remdesevir, ritonar and tocilizumab should be regularly moni-
tored via LFTs, as these drugs have a documented hepatotoxicity.47 
It appears that a greater severity of SARS- CoV- 2 infection and ad-
vanced age, together with poly- therapy, predisposes patients to a 
more severe liver dysfunction. The increase in transaminases, in par-
ticular AST, is more common in adult males than in female patients. 
Therefore, COVID- 19 patients who have pre- existing liver diseases 
should be adequately monitored and drug- to- drug interactions 
should be checked before starting COVID- 19 treatments, including 
antiviral agents, especially in patients with advanced chronic liver. 
A useful checker tool is available at: https://www.COVID 19- drugi 
ntera ctions.org/checker
6  | CONCLUSIONS
The underlying mechanisms of liver injury during SARS- CoV- 2 re-
main unclear. Among the most probable hypotheses are viral cyto-
pathic effects, immune imbalance and cytokine storm, ischaemia 
and/or hypoxia- reperfusion injury and, finally DILI. A recent meta- 
analysis reported that incidence of DILI in Covid- 19 hospitalised pa-
tients was of 25%. From a clinical point of view, great care should be 
taken when monitoring patients to prevent the onset of liver injury 
and avoid the administration of hepatotoxic drugs. Some studies 
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have reported an increased incidence of acute kidney injury after 
COVID- 19, possibly due to the presence of SARS- CoV- 2- induced 
inflammation. Damage to the liver and kidneys can affect expecta-
tions regarding the metabolism, excretion, dose and concentration 
of drugs, thus making it difficult to establish the correct therapeutic 
dose of the drugs without increasing the risk of toxicity.61,62
Continuing studies on severity, mortality and the incidence of 
complications should be performed in order to understand how pre- 
existing liver conditions may influence and worsen the progression 
of liver disease in patients with SARS- CoV- 2 infection.
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